Vertex Pharma (VRTX) Misses Q4 EPS by 8c, Revenues Beat; Provides FY21 Product Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. AAPL
3. LITE
4. PLTR
5. REGN
6. MRVL
7. ABBV
8. CL
9. CHKP
10. TFII

Go back to Vertex Pharma (VRTX) Misses Q4 EPS by 8c, Revenues Beat; Provides FY21 Product Revenue Outlook

Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results

February 1, 2021 4:01 PM EST

-Full-year 2020 GAAP product revenues of $6.20 billion-

-Full-year 2020 non-GAAP product revenues of $6.20 billion, a 55% increase compared to full-year 2019-

-Company provides full-year 2021 product revenue guidance of $6.7 to $6.9 billion-

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2020 and provided full-year 2021 financial guidance.

"Our achievements in 2020 were marked by a significant increase in the number of people treated with the triple... More